Literature DB >> 9915319

Rocuronium-induced neuromuscular block is affected by chronic carbamazepine therapy.

A Spacek1, F X Neiger, C G Krenn, K Hoerauf, H G Kress.   

Abstract

BACKGROUND: Patients on chronic anticonvulsant drugs are relatively resistant to certain nondepolarizing neuromuscular blockers such as pancuronium, vecuronium, pipecuronium, doxacurium, or metocurine, but not resistant to mivacurium and atracurium. This study investigated the influence of chronic carbamazepine therapy on the neuromuscular block induced by the new muscle relaxant rocuronium.
METHODS: Twenty-two otherwise healthy individuals scheduled for neurosurgical operations were studied: 11 of them were on chronic treatment with carbamazepine; the others served as control subjects. The median duration of carbamazepine therapy was 9 weeks (range, 4-312 weeks). After premedication with oral diazepam, anesthesia was induced with fentanyl and thiopental and maintained with nitrous oxide/oxygen and 0.5% inspired isoflurane. Rocuronium, 0.6 mg/kg (2 x ED95), was given for intubation. The ulnar nerve was stimulated, and the evoked electromyogram recorded using a Datex NMT monitor.
RESULTS: Based on the response to the first of four stimuli, neither the lag time nor the onset-time differed between the two groups. However, the intervals of recovery to 10%, 25%, 50%, and 75% of the baseline response and the recovery index (RI, 25%-75%) were significantly shorter in patients on chronic carbamazepine therapy.
CONCLUSIONS: The authors conclude that the duration of the rocuronium-induced neuromuscular block is significantly shortened by preceding chronic carbamazepine therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9915319     DOI: 10.1097/00000542-199901000-00016

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  6 in total

Review 1.  Antiepileptic-induced resistance to neuromuscular blockers: mechanisms and clinical significance.

Authors:  Sulpicio G Soriano; J A Jeevendra Martyn
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  The SLCO1A2 -189_-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries.

Authors:  A C C Costa; E B Coelho; V L Lanchote; B V Correia; J T Abumansur; G R Lauretti; N V de Moraes
Journal:  Eur J Clin Pharmacol       Date:  2017-04-14       Impact factor: 2.953

3.  Anesthetic experience using total intravenous anesthesia in a patient with Isaacs' syndrome -A case report-.

Authors:  Young Mi Kim; Sang Hoon Lee; Cheol Sig Han; Eun Mi Choi; Young Ryong Choi; Mi Hwa Chung
Journal:  Korean J Anesthesiol       Date:  2013-02-15

4.  Comparison of Different Induction Doses of Rocuronium and Vecuronium in Neuroanaesthesia Practice.

Authors:  Behiye Doğruel; Giray Varnalı; Çiğdem Selek; Lütfi Telci; İbrahim Özkan Akıncı
Journal:  Turk J Anaesthesiol Reanim       Date:  2013-05-23

5.  Pharmacokinetic-pharmacodynamic modeling of the influence of chronic phenytoin therapy on the rocuronium bromide response in patients undergoing brain surgery.

Authors:  Juan Fernández-Candil; Pedro L Gambús; Iñaki F Trocóniz; Ricard Valero; Enrique Carrero; Lorea Bueno; Neus Fábregas
Journal:  Eur J Clin Pharmacol       Date:  2008-06-03       Impact factor: 2.953

6.  Pharmacological interventions for acceleration of the onset time of rocuronium: a meta-analysis.

Authors:  Jing Dong; Lingqi Gao; Wenqing Lu; Zifeng Xu; Jijian Zheng
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.